Published in Blood on February 01, 2000
Impact of Microparticles on Postoperative Complications in Surgical Patients | NCT00677781
MicroRNAs are transported in plasma and delivered to recipient cells by high-density lipoproteins. Nat Cell Biol (2011) 8.21
Detection of microRNA expression in human peripheral blood microvesicles. PLoS One (2008) 8.04
Membrane vesicles, current state-of-the-art: emerging role of extracellular vesicles. Cell Mol Life Sci (2011) 5.42
Accumulation of tissue factor into developing thrombi in vivo is dependent upon microparticle P-selectin glycoprotein ligand 1 and platelet P-selectin. J Exp Med (2003) 3.61
Biological properties of extracellular vesicles and their physiological functions. J Extracell Vesicles (2015) 3.02
Human malarial disease: a consequence of inflammatory cytokine release. Malar J (2006) 2.36
Microparticles in hemostasis and thrombosis. Circ Res (2011) 2.26
Alteration of marrow cell gene expression, protein production, and engraftment into lung by lung-derived microvesicles: a novel mechanism for phenotype modulation. Stem Cells (2007) 1.92
Pro-coagulant state resulting from high levels of soluble P-selectin in blood. Proc Natl Acad Sci U S A (2000) 1.90
Macrophage microvesicles induce macrophage differentiation and miR-223 transfer. Blood (2012) 1.80
Antibacterial effect of microvesicles released from human neutrophilic granulocytes. Blood (2012) 1.76
Extracellular heat shock proteins, cellular export vesicles, and the Stress Observation System: a form of communication during injury, infection, and cell damage. It is never known how far a controversial finding will go! Dedicated to Ferruccio Ritossa. Cell Stress Chaperones (2010) 1.69
Endothelial dysfunction caused by circulating microparticles from patients with metabolic syndrome. Am J Pathol (2008) 1.51
Monocytic microparticles activate endothelial cells in an IL-1β-dependent manner. Blood (2011) 1.48
Circulating erythrocyte-derived microparticles are associated with coagulation activation in sickle cell disease. Haematologica (2009) 1.46
Free hemoglobin concentration in severe sepsis: methods of measurement and prediction of outcome. Crit Care (2012) 1.33
Vascular smooth muscle-derived tissue factor is critical for arterial thrombosis after ferric chloride-induced injury. Blood (2008) 1.32
Synovial microparticles from arthritic patients modulate chemokine and cytokine release by synoviocytes. Arthritis Res Ther (2005) 1.28
Microparticles: a critical component in the nexus between inflammation, immunity, and thrombosis. Semin Immunopathol (2011) 1.26
Pre-analytical and analytical variables affecting the measurement of plasma-derived microparticle tissue factor activity. Thromb Res (2011) 1.25
Tissue factor as an initiator of coagulation and inflammation in the lung. Crit Care (2008) 1.22
Cellular phenotype switching and microvesicles. Adv Drug Deliv Rev (2010) 1.21
Ectosomes as modulators of inflammation and immunity. Clin Exp Immunol (2010) 1.19
Characterizing blood microparticles: technical aspects and challenges. Vasc Health Risk Manag (2008) 1.17
Plasma gelsolin depletion and circulating actin in sepsis: a pilot study. PLoS One (2008) 1.17
ABCA1 gene deletion protects against cerebral malaria: potential pathogenic role of microparticles in neuropathology. Am J Pathol (2005) 1.12
Increased platelet and microparticle activation in HIV infection: upregulation of P-selectin and tissue factor expression. J Acquir Immune Defic Syndr (2012) 1.11
Microparticle-induced release of B-lymphocyte regulators by rheumatoid synoviocytes. Arthritis Res Ther (2009) 1.09
Microparticles: markers and mediators of sepsis-induced microvascular dysfunction, immunosuppression, and AKI. Kidney Int (2015) 1.09
Platelet-derived exosomes from septic shock patients induce myocardial dysfunction. Crit Care (2007) 1.07
Extracellular vesicle profiling and their use as potential disease specific biomarker. Front Immunol (2014) 1.05
On the origin of microparticles: From "platelet dust" to mediators of intercellular communication. Pulm Circ (2013) 1.05
Protection against cerebral malaria by the low-molecular-weight thiol pantethine. Proc Natl Acad Sci U S A (2008) 1.04
Tissue factor activity is increased in a combined platelet and microparticle sample from cancer patients. Thromb Res (2008) 1.04
Shiga toxin and lipopolysaccharide induce platelet-leukocyte aggregates and tissue factor release, a thrombotic mechanism in hemolytic uremic syndrome. PLoS One (2009) 1.04
Analyzing the circulating microRNAs in exosomes/extracellular vesicles from serum or plasma by qRT-PCR. Methods Mol Biol (2013) 1.03
Elevated procoagulant microparticles expressing endothelial and platelet markers in essential thrombocythemia. Haematologica (2009) 1.03
Release of annexin V-binding membrane microparticles from cultured human umbilical vein endothelial cells after treatment with camptothecin. BMC Cell Biol (2002) 1.02
Bench-to-bedside review: circulating microparticles--a new player in sepsis? Crit Care (2010) 1.02
"Small Talk" in the Innate Immune System via RNA-Containing Extracellular Vesicles. Front Immunol (2014) 1.01
CD39 is incorporated into plasma microparticles where it maintains functional properties and impacts endothelial activation. Br J Haematol (2008) 1.00
High levels of circulating leukocyte microparticles are associated with better outcome in acute respiratory distress syndrome. Crit Care (2011) 1.00
Cell-derived microparticles in atherosclerosis: biomarkers and targets for pharmacological modulation? J Cell Mol Med (2012) 0.99
Circulating microparticles and endogenous estrogen in newly menopausal women. Climacteric (2009) 0.98
Characterization of membrane-shed microvesicles from cytokine-stimulated β-cells using proteomics strategies. Mol Cell Proteomics (2012) 0.97
Clinical significance of procoagulant microparticles. J Intensive Care (2015) 0.94
Zebrafish thrombocytes: functions and origins. Adv Hematol (2012) 0.93
Sepsis-associated disseminated intravascular coagulation and thromboembolic disease. Mediterr J Hematol Infect Dis (2010) 0.91
Microparticle analysis in disorders of hemostasis and thrombosis. Cytometry A (2015) 0.89
The clinical and functional relevance of microparticles induced by activated protein C treatment in sepsis. Crit Care (2011) 0.89
The role of microparticles in chronic obstructive pulmonary disease. Int J Chron Obstruct Pulmon Dis (2014) 0.89
Prothrombotic markers and early spontaneous recanalization in ST-segment elevation myocardial infarction. Thromb Haemost (2007) 0.88
Microparticles in endothelial cell and vascular homeostasis: are they really noxious? Haematologica (2009) 0.87
Calpastatin controls polymicrobial sepsis by limiting procoagulant microparticle release. Am J Respir Crit Care Med (2012) 0.86
Microvesicles at the crossroads between infection and cardiovascular diseases. J Cardiovasc Pharmacol (2012) 0.86
Neutrophil derived microvesicles: emerging role of a key mediator to the immune response. Endocr Metab Immune Disord Drug Targets (2014) 0.86
Enhanced expression of cell-specific surface antigens on endothelial microparticles in sepsis-induced disseminated intravascular coagulation. Shock (2015) 0.85
Endocytosis and intracellular processing of platelet microparticles by brain endothelial cells. J Cell Mol Med (2012) 0.85
The role of cell death in the pathogenesis of autoimmune disease: HMGB1 and microparticles as intercellular mediators of inflammation. Mod Rheumatol (2008) 0.85
Endotoxin-induced monocytic microparticles have contrasting effects on endothelial inflammatory responses. PLoS One (2014) 0.84
Role of the hemostatic system on sickle cell disease pathophysiology and potential therapeutics. Hematol Oncol Clin North Am (2014) 0.84
Fetal hemoglobin and hydroxycarbamide moduate both plasma concentration and cellular origin of circulating microparticles in sickle cell anemia children. Haematologica (2013) 0.84
Circulating annexin V positive microparticles in patients after successful cardiopulmonary resuscitation. Crit Care (2011) 0.84
Platelets and Their Interactions with Other Immune Cells. Compr Physiol (2015) 0.83
Microparticles as potential biomarkers of cardiovascular disease. Arq Bras Cardiol (2015) 0.82
Microparticles provide a novel biomarker to predict severe clinical outcomes of dengue virus infection. J Virol (2014) 0.81
Changing world of neutrophils. Pflugers Arch (2013) 0.81
Leukocyte- and platelet-derived microvesicle interactions following in vitro and in vivo activation of toll-like receptor 4 by lipopolysaccharide. PLoS One (2011) 0.80
The endothelium, a protagonist in the pathophysiology of critical illness: focus on cellular markers. Biomed Res Int (2014) 0.80
Microparticle Shedding from Neural Progenitor Cells and Vascular Compartment Cells Is Increased in Ischemic Stroke. PLoS One (2016) 0.80
Autocrine activation of human monocyte/macrophages by monocyte-derived microparticles and modulation by PPARγ ligands. Br J Pharmacol (2012) 0.79
Microparticles as immune regulators in infectious disease - an opinion. Front Immunol (2011) 0.78
Circulating membrane-derived microvesicles in redox biology. Free Radic Biol Med (2014) 0.78
Effects of progesterone and estradiol sex hormones on the release of microparticles by RAW 264.7 macrophages stimulated by Poly(I:C). Clin Vaccine Immunol (2011) 0.78
Microparticles: new light shed on the understanding of venous thromboembolism. Acta Pharmacol Sin (2014) 0.78
Is the neutrophil a 'prima donna' in the procoagulant process during sepsis? Crit Care (2014) 0.78
A novel role for pro-coagulant microvesicles in the early host defense against streptococcus pyogenes. PLoS Pathog (2013) 0.78
[Cardiovascular manifestations in rheumatoid arthritis]. Z Rheumatol (2005) 0.77
Alterations of the Erythrocyte Membrane during Sepsis. Crit Care Res Pract (2012) 0.77
Circulating Endothelial Microparticles: A Key Hallmark of Atherosclerosis Progression. Scientifica (Cairo) (2016) 0.77
Platelet-derived microparticles generated by neonatal extracorporeal membrane oxygenation systems. ASAIO J (2014) 0.77
Tissue factor-bearing microparticles and CA19.9: two players in pancreatic cancer-associated thrombosis? Br J Cancer (2016) 0.76
Circulating microparticles, protein C, free protein S and endothelial vascular markers in children with sickle cell anaemia. J Extracell Vesicles (2015) 0.76
Extracellular vesicles in liver pathobiology: Small particles with big impact. Hepatology (2016) 0.76
Cell-derived vesicles for drug therapy and diagnostics: opportunities and challenges. Nano Today (2015) 0.75
Circulating microparticles in children with sickle cell anemia: a heterogeneous procoagulant storm directed by hemolysis and fetal hemoglobin. Haematologica (2013) 0.75
Comparison of microRNA expression profiles in K562-cells-derived microvesicles and parental cells, and analysis of their roles in leukemia. Oncol Lett (2016) 0.75
A low balance between microparticles expressing tissue factor pathway inhibitor and tissue factor is associated with thrombosis in Behçet's Syndrome. Sci Rep (2016) 0.75
Circulating Microvesicles Are Elevated Acutely following Major Burns Injury and Associated with Clinical Severity. PLoS One (2016) 0.75
Activation of Endothelial Pro-resolving Anti-Inflammatory Pathways by Circulating Microvesicles from Non-muscular Myosin Light Chain Kinase-Deficient Mice. Front Pharmacol (2016) 0.75
Tumour-associated circulating microparticles: A novel liquid biopsy tool for screening and therapy monitoring of colorectal carcinoma and other epithelial neoplasia. Oncotarget (2016) 0.75
Platelet-, monocyte-derived and tissue factor-carrying circulating microparticles are related to acute myocardial infarction severity. PLoS One (2017) 0.75
Extracellular vesicles in renal disease. Nat Rev Nephrol (2017) 0.75
Insect-sting challenge in 324 subjects with a previous anaphylactic reaction: current criteria for insect-venom hypersensitivity do not predict the occurrence and the severity of anaphylaxis. J Allergy Clin Immunol (1994) 5.14
C-reactive protein as a cardiovascular risk factor: more than an epiphenomenon? Circulation (1999) 4.40
Randomised trial of personalised computer based information for cancer patients. BMJ (1999) 3.82
Anti-inflammatory cytokine profile and mortality in febrile patients. Lancet (1998) 3.71
Anaphylactic shock after insect-sting challenge in 138 persons with a previous insect-sting reaction. Ann Intern Med (1993) 3.42
Wegener's granulomatosis autoantibodies identify a novel diisopropylfluorophosphate-binding protein in the lysosomes of normal human neutrophils. J Clin Invest (1989) 3.34
Successful aging in the oldest old: Who can be characterized as successfully aged? Arch Intern Med (2001) 3.16
The definition of anemia in older persons. JAMA (1999) 3.09
Morbidity and mortality in adults with idiopathic thrombocytopenic purpura. Blood (2001) 2.96
Activation of coagulation after administration of tumor necrosis factor to normal subjects. N Engl J Med (1990) 2.82
Endotoxaemia: an early predictor of septicaemia in febrile patients. Lancet (1988) 2.67
Microparticles in cardiovascular diseases. Cardiovasc Res (2003) 2.62
Measuring circulating cell-derived microparticles. J Thromb Haemost (2004) 2.61
Cardioprotective effect of hormone replacement therapy in postmenopausal women: is the evidence biased? BMJ (1994) 2.54
Total cholesterol and risk of mortality in the oldest old. Lancet (1997) 2.50
Serum levels of interleukin-6 and acute phase responses. Lancet (1987) 2.44
Activation of the complement system during and after cardiopulmonary bypass surgery: postsurgery activation involves C-reactive protein and is associated with postoperative arrhythmia. Circulation (1997) 2.41
Single vs. swarm detection of microparticles and exosomes by flow cytometry. J Thromb Haemost (2012) 2.39
Cell-derived microparticles circulate in healthy humans and support low grade thrombin generation. Thromb Haemost (2001) 2.38
Experimental endotoxemia in humans: analysis of cytokine release and coagulation, fibrinolytic, and complement pathways. Blood (1990) 2.33
Insect-sting challenge in 138 patients: relation between clinical severity of anaphylaxis and mast cell activation. J Allergy Clin Immunol (1992) 2.29
Statins for prevention of stroke. Lancet (1998) 2.26
Optical and non-optical methods for detection and characterization of microparticles and exosomes. J Thromb Haemost (2010) 2.19
The design of a prospective study of Pravastatin in the Elderly at Risk (PROSPER). PROSPER Study Group. PROspective Study of Pravastatin in the Elderly at Risk. Am J Cardiol (1999) 2.18
Interleukin 10 secretion in relation to human IL-10 locus haplotypes. Proc Natl Acad Sci U S A (1998) 2.18
Asthma deaths in New Zealand: whodunnit? Lancet (1995) 2.17
Serum inflammatory proteins and cognitive decline in older persons. Neurology (2005) 2.11
Increased levels of factor VIII and fibrinogen in patients with venous thrombosis are not caused by acute phase reactions. Thromb Haemost (1999) 2.04
Protection against influenza after annually repeated vaccination: a meta-analysis of serologic and field studies. Arch Intern Med (1999) 2.01
[Anaphylactic reactions following insect stings: clinical aspects, course and treatment]. Ned Tijdschr Geneeskd (1993) 1.96
C-reactive protein colocalizes with complement in human hearts during acute myocardial infarction. Circulation (1997) 1.94
Human monoclonal antibodies in sepsis. Neth J Med (1991) 1.94
Impact of mild cognitive impairment on survival in very elderly people: cohort study. BMJ (1997) 1.91
Particle size distribution of exosomes and microvesicles determined by transmission electron microscopy, flow cytometry, nanoparticle tracking analysis, and resistive pulse sensing. J Thromb Haemost (2014) 1.90
Inflammatory markers in late-life depression: results from a population-based study. J Affect Disord (2007) 1.89
Evidence for the existence of protomers in the assembly of encephalomyocarditis virus. J Virol (1975) 1.86
Stroke, statins, and cholesterol. A meta-analysis of randomized, placebo-controlled, double-blind trials with HMG-CoA reductase inhibitors. Stroke (1997) 1.86
Complement activation plays a key role in the side-effects of rituximab treatment. Br J Haematol (2001) 1.86
Novel single nucleotide polymorphisms in the distal IL-10 promoter affect IL-10 production and enhance the risk of systemic lupus erythematosus. J Immunol (2001) 1.84
Complement activation in patients with rheumatoid arthritis mediated in part by C-reactive protein. Arthritis Rheum (2001) 1.84
Value of myoglobin, troponin T, and CK-MBmass in ruling out an acute myocardial infarction in the emergency room. Circulation (1995) 1.82
Deficiencies of coagulation-inhibiting and fibrinolytic proteins in outpatients with deep-vein thrombosis. N Engl J Med (1990) 1.76
Cellular microparticles: new players in the field of vascular disease? Eur J Clin Invest (2004) 1.74
C-reactive protein is a strong but nonspecific risk factor of fatal stroke in elderly persons. Arterioscler Thromb Vasc Biol (2000) 1.70
Kinetics of dengue virus-specific serum immunoglobulin classes and subclasses correlate with clinical outcome of infection. J Clin Microbiol (2001) 1.70
Proinflammatory effects of IL-10 during human endotoxemia. J Immunol (2000) 1.69
Cell-derived microparticles generated in patients during cardiopulmonary bypass are highly procoagulant. Circulation (1997) 1.67
Microparticles from patients with multiple organ dysfunction syndrome and sepsis support coagulation through multiple mechanisms. Thromb Haemost (2001) 1.65
Plasma elastase alpha 1-antitrypsin and lactoferrin in sepsis: evidence for neutrophils as mediators in fatal sepsis. J Lab Clin Med (1992) 1.65
Continuous 48-h C1-inhibitor treatment, following reperfusion therapy, in patients with acute myocardial infarction. Eur Heart J (2002) 1.65
Elimination of interleukin 6 attenuates coagulation activation in experimental endotoxemia in chimpanzees. J Exp Med (1994) 1.64
Local activation of coagulation and inhibition of fibrinolysis in the lung during ventilator associated pneumonia. Thorax (2004) 1.63
C1-esterase inhibitor substitution in sepsis. Lancet (1992) 1.61
Prediction of mortality in febrile medical patients: How useful are systemic inflammatory response syndrome and sepsis criteria? Chest (1998) 1.61
Apoptosis in myocardial ischaemia and infarction. J Clin Pathol (2002) 1.59
Risk factor profiles in patients with different clinical manifestations of venous thromboembolism: a focus on the factor V Leiden mutation. Thromb Haemost (1996) 1.58
Differences in age, site distribution, and sex between nodular and superficial basal cell carcinoma indicate different types of tumors. J Invest Dermatol (1998) 1.54
C1-Esterase inhibitor: an anti-inflammatory agent and its potential use in the treatment of diseases other than hereditary angioedema. Pharmacol Rev (2000) 1.52
Relation between smoking and skin cancer. J Clin Oncol (2001) 1.50
C-reactive protein and complement depositions in human infarcted myocardium are more extensive in patients with reinfarction or upon treatment with reperfusion. Eur J Clin Invest (2004) 1.50
Inhibition of endotoxin-induced activation of coagulation and fibrinolysis by pentoxifylline or by a monoclonal anti-tissue factor antibody in chimpanzees. J Clin Invest (1994) 1.50
Acute lung injury after aortic surgery: the relation between lung and leg microvascular permeability to 111indium-labelled transferrin and circulating mediators. Thorax (1997) 1.48
The glomerular deposition of PAS positive material correlates with renal function in human kidney diseases. Clin Nephrol (1997) 1.48
Interleukin-6 stimulates coagulation, not fibrinolysis, in humans. Thromb Haemost (1996) 1.47
Plasma levels of the chemokines monocyte chemotactic proteins-1 and -2 are elevated in human sepsis. Blood (1995) 1.47
Biophysical studies on rhinovirus and poliovirus. I. Morphology of viral ribonucleoprotein. J Virol (1968) 1.46
Cell-derived microparticles contain caspase 3 in vitro and in vivo. J Thromb Haemost (2005) 1.45
Cognitive function in the oldest old: women perform better than men. J Neurol Neurosurg Psychiatry (2001) 1.44
Proteolytic inactivation of alpha 1-antitrypsin and alpha 1-antichymotrypsin by neutrophils in arthritic joints. Arthritis Rheum (1993) 1.44
TNF-alpha promoter polymorphisms, production and susceptibility to multiple sclerosis in different groups of patients. J Neuroimmunol (1997) 1.43
Cardiovascular side effects of inhaled salbutamol in hypoxic asthmatic patients. Thorax (2001) 1.41
Human cell-derived microparticles promote thrombus formation in vivo in a tissue factor-dependent manner. J Thromb Haemost (2003) 1.41
Effect of apolipoprotein E and insulin resistance on VLDL particles in combined hyperlipidemic patients. Atherosclerosis (1996) 1.40
Extracellular granzymes A and B in humans: detection of native species during CTL responses in vitro and in vivo. J Immunol (1998) 1.39
Melanocortin-1 receptor gene variants determine the risk of nonmelanoma skin cancer independently of fair skin and red hair. Am J Hum Genet (2001) 1.39
Mortality in patients with epilepsy: 40 years of follow up in a Dutch cohort study. J Neurol Neurosurg Psychiatry (1999) 1.39
[The prioritisation of genetic screening with primary haemochromatosis as an example]. Ned Tijdschr Geneeskd (2003) 1.39
Purpura fulminans and symmetrical peripheral gangrene caused by Capnocytophaga canimorsus (formerly DF-2) septicemia--a complication of dog bite. Medicine (Baltimore) (1991) 1.38
[Cellular microparticles and blood-vessel damage. II. Functional characteristics and clinical significance]. Ned Tijdschr Geneeskd (2004) 1.38
[Thromboembolic complications of central venous catheters]. Ned Tijdschr Geneeskd (1996) 1.38
Complement activation in amyloid plaques in Alzheimer's dementia. Virchows Arch B Cell Pathol Incl Mol Pathol (1989) 1.38
Picornaviridae. Intervirology (1974) 1.36
Activation of the complement system during immunotherapy with recombinant IL-2. Relation to the development of side effects. J Immunol (1990) 1.34
The outcome of absence epilepsy: a meta-analysis. Neurology (1996) 1.34
Production and characterization of monoclonal antibodies raised against recombinant human granzymes A and B and showing cross reactions with the natural proteins. J Immunol Methods (1993) 1.33
Quality and quantity of the humoral immune response in healthy elderly and young subjects after annually repeated influenza vaccination. J Infect Dis (1999) 1.33
Cross sectional survey of patients' satisfaction with information about cancer. BMJ (1999) 1.33
ADAMTS-13, von Willebrand factor and related parameters in severe sepsis and septic shock. J Thromb Haemost (2007) 1.32
A C1-inhibitor-complex assay (INCA): a method to detect C1 activation in vitro and in vivo. J Immunol (1981) 1.31
Activity of ICI 195,739--a novel, orally active bistriazole--in rodent models of fungal and protozoal infections. Ann N Y Acad Sci (1988) 1.31